Amoxicillin plus Clavulanic Acid Vs Amoxicillin in the Treatment of Community Acquired Pneumonia in Children: A Double-Blind, Randomized, Controlled Trial

Article Sidebar

PDF
Published: Jun 8, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i6-06
Keywords:
Community Acquired Pneumonia (CAP); Amoxycillin; Amoxycillin plus Clavulanic acid; Amoxyclav

Main Article Content

A. Agarwal MD
Departments of Pediatrics and Radiodiagnosis#, Era’s Lucknow Medical College & Hospital, Lucknow-226003, India
MMA Faridi MD DCH
Departments of Pediatrics and Radiodiagnosis#, Era’s Lucknow Medical College & Hospital, Lucknow-226003, India
S Shamsi DNB
Departments of Pediatrics and Radiodiagnosis#, Era’s Lucknow Medical College & Hospital, Lucknow-226003, India
S Khanduri MD
Departments of Pediatrics and Radiodiagnosis#, Era’s Lucknow Medical College & Hospital, Lucknow-226003, India

Abstract

WHO recommendations for the management of Community Acquired Pneumonia (CAP) have been revised since 2014, amoxicillin is recommended as first choice for oral antibiotic therapy in domiciliary treatment of children. This study was planned to compare cure rate of oral amoxicillin plus clavulanic acid vs oral amoxicillin in children with CAP.


Children aged 6- 36 mo, presenting with the clinical features consistent with the diagnosis of CAP were enrolled. Patients were given oral amoxicillin or amoxycillin plus clavulanic acid for 5 d and followed at 48h, 5th d and 2 mo. The cure rate, adverse reactions and recurrence were assessed and analysed for these two drugs.


The cure rate of CAP in amoxicillin plus clavulanic acid group was significantly higher as compared to amoxicillin group (93.88% vs 79.17%, p 0.013). The chances of cure rate increased by 15.3% for children receiving oral amoxicillin plus clavulanic acid. Only mild side effects like diarrhea (22.1%), nausea (9.6%), vomiting (5.7%), and maculo-papular rash (2.9%) were observed in both the groups. All the cured children were followed up to 2 mo and none had recurrence of symptoms.

Article Details

How to Cite
A. Agarwal MD, MMA Faridi MD DCH, S Shamsi DNB, & S Khanduri MD. (2022). Amoxicillin plus Clavulanic Acid Vs Amoxicillin in the Treatment of Community Acquired Pneumonia in Children: A Double-Blind, Randomized, Controlled Trial. International Journal of Medical Science and Clinical Research Studies, 2(6), 473–477. https://doi.org/10.47191/ijmscrs/v2-i6-06
Issue
Vol. 2 No. 6 (2022): Volume 02 Issue 06 June 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. United Nations Inter-Agency Group for Child Mortality Estimation. Levels & Trends in Child Mortality. 2021. https://data.unicef.org/resources/levels-and-trends-in-child-mortality. Accessed on 25th January, 2022.

II. Matthew S. Kelly, Thomas J. Sandora. Community-Acquired Pneumonia. In: Robert M. Kliegman, Joseph St. Geme. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier, 2020.

III. WHO. Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. World Health Organization, Geneva, 2014.

IV. Jibril HB, Ifere OA, Odumah DU. An open, comparative evaluation of amoxycillin and amoxycillin plus clavulanic acid ('Augmentin') in the treatment of bacterial pneumonia in children. Curr Med Res Opin. 1989;11(9):585-592. doi:10.1185/03007998909112675

V. Aurangzeb B, Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children. J Coll Physicians Surg Pak. 2003;13(12):704-707.

VI. Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013 Jun 4;2013(6):CD004874. doi:10.1002/14651858.CD004874.pub4.

VII. Sukumaran TU, Das RR, Warankar S. Community-acquired pneumonia. Standard treatment guidelines. IAP; 2022. https://iapindia.org/pdf/Ch-011-Community-Acquired-Pneumonia.pdf. Accessed on 30th January,2022.